Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.37 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 4/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125276 | 0.87 | POLB (0.36) | TAAR1SLC6A2ANPEPRNPEPDNPEP | |
| SCHEMBL5121369 | 0.86 | SLC6A2 (0.47) | TAAR1SLC6A2ANPEPRNPEPDNPEP | |
| SCHEMBL5117675 | 0.86 | TRPA1 (0.37) | TAAR1MAPTANPEPRNPEPDNPEP | |
| SCHEMBL5124475 | 0.79 | TAAR1 (0.53) | TAAR1SLC6A2ESR1ESR2OPRK1 | |
| SCHEMBL5121069 | 0.77 | HPGD (0.39) | TAAR1SLC6A2MAPTSMN1; SMN2ANPEP | |
| SCHEMBL5117837 | 0.76 | SIGMAR1 (0.42) | TAAR1ANPEPRNPEPDNPEPLAP3 | |
| SCHEMBL5139582 | 0.72 | TAAR1 (0.36) | TAAR1SLC6A2ESR1OPRK1SIGMAR1 | |
| SCHEMBL6274018 | 0.70 | ANPEP (0.57) | TAAR1SLC6A2ANPEPRNPEPDNPEP | |
| SCHEMBL1013284 | 0.69 | TAAR1 (0.55) | TAAR1SLC6A2ESR1ESR2OPRK1 | |
| SCHEMBL1013285 | 0.69 | TAAR1 (0.55) | TAAR1SLC6A2ESR1ESR2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | disclosed |
| US-7294642-B2 | 1,3-Diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | BACE1, APP, BACE2 | TAAR1 3920/4885SLC6A2 1728/4885ESR1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.